| Q36943923 | A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells |
| Q38714821 | A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity. |
| Q33841127 | A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection |
| Q33724878 | A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside |
| Q93084804 | A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma |
| Q27026836 | Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials |
| Q27006934 | Adoptive T-cell therapy for Leukemia |
| Q34279672 | Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation |
| Q35866682 | An Immunocompetent Mouse Model for MLL/AF9 Leukemia Reveals the Potential of Spontaneous Cytotoxic T-Cell Response to an Antigen Expressed in Leukemia Cells |
| Q53659200 | Analysis of HLA class Ia transcripts in human leukaemias. |
| Q39243052 | Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies |
| Q35817394 | Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis. |
| Q37384745 | Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide |
| Q36662079 | Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation |
| Q74263582 | Benign autoimmunity to combat malignancy |
| Q35828737 | Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease |
| Q37587956 | CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies? |
| Q36694901 | Can immunotherapy specifically target acute myeloid leukemic stem cells? |
| Q34820068 | Cancer immunotherapy targeting WT1 protein |
| Q42538957 | Changes in expression of WT1 during induced differentiation of the acute myeloid leukemia cell lines by treatment with 5-aza-2'-deoxycytidine and all-trans retinoic acid |
| Q37132892 | Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation |
| Q64245424 | Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML) |
| Q57180053 | Chromosome Y-encoded antigens associate with acute graft-versus-host disease in sex-mismatched stem cell transplant |
| Q93065274 | DNA Methylation Readers and Cancer: Mechanistic and Therapeutic Applications |
| Q37467831 | Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo |
| Q37272398 | Detection of low avidity CD8(+) T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramers |
| Q33587590 | Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice |
| Q36011784 | Exploiting T cell receptor genes for cancer immunotherapy |
| Q34803707 | Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy |
| Q34645898 | Genetically engineered T cells for the treatment of cancer |
| Q27026627 | Genetically modified T cells in cancer therapy: opportunities and challenges |
| Q33770125 | Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia |
| Q37445265 | Graft-versus-leukemia effect of nonmyeloablative stem cell transplantation |
| Q35990687 | Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia |
| Q35880618 | Haematological malignancies: at the forefront of immunotherapeutic innovation |
| Q36952252 | Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy. |
| Q36574157 | Heterogeneity in the molecular pathogenesis of paroxysmal nocturnal hemoglobinuria (PNH) syndromes and expansion mechanism of a PNH clone |
| Q37119914 | High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow |
| Q34842175 | Immunological weapons against acute myeloid leukaemia |
| Q37738466 | Immunotherapeutic strategies in chronic myeloid leukemia |
| Q37194498 | Immunotherapy for myeloid leukemias: current status and future directions |
| Q37106769 | Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain |
| Q37535549 | Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression |
| Q36781571 | Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine |
| Q82845503 | Induction of antigen-specific cytotoxic T lymphocytes by using monocyte-derived DCs transfected with in vitro-transcribed WT1 or SART1 mRNA |
| Q34068404 | Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination |
| Q64275599 | Inhibition of Heme Oxygenase-1 Activity Enhances Wilms Tumor-1-Specific T-Cell Responses in Cancer Immunotherapy |
| Q34214817 | Leukemia vaccines |
| Q36384606 | Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. |
| Q34180369 | Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemot |
| Q36194241 | Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias |
| Q39411920 | Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors |
| Q37766303 | Molecular immunology lessons from therapeutic T-cell receptor gene transfer |
| Q21144124 | Non-natural and photo-reactive amino acids as biochemical probes of immune function |
| Q38664735 | Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock? |
| Q37171413 | Peptide epitope identification for tumor-reactive CD4 T cells |
| Q37850382 | Peptide vaccine therapy for leukemia |
| Q26777032 | Peptide-Based Treatment: A Promising Cancer Therapy |
| Q35847917 | Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome |
| Q40725673 | Priming of PRAME- and WT1-specific CD8(+) T cells in healthy donors but not in AML patients in complete remission: Implications for immunotherapy |
| Q35000449 | Prognostic significance of specific anti-WT1 IgG antibody level in plasma in patients with ovarian carcinoma |
| Q35041705 | Prospects for immunotherapy of malignant disease |
| Q91643038 | Reader-free ELISPOT assay for immuno-monitoring in peptide-based cancer vaccine immunotherapy |
| Q27005765 | Recent advance in antigen-specific immunotherapy for acute myeloid leukemia |
| Q35553553 | Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? |
| Q34612637 | Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies. |
| Q40572007 | Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer |
| Q38362636 | Review of the Results of WT1 Peptide Vaccination Strategies for Myelodysplastic Syndromes and Acute Myeloid Leukemia from Nine Different Studies |
| Q37107843 | Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies |
| Q34455397 | Science, medicine, and the future: Cellular immunotherapy for cancer |
| Q27676136 | Structural and energetic evidence for highly peptide-specific tumor antigen targeting via allo-MHC restriction |
| Q42617564 | Studies of Wilms' Tumor (WT1) Gene Expression in Adult Acute Leukemias in Singapore |
| Q92337101 | T-Cell Receptor-Based Immunotherapy for Hematologic Malignancies |
| Q34707452 | T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy |
| Q28081611 | T-cell receptor gene therapy--ready to go viral? |
| Q42938317 | T-cell receptor gene transfer for the treatment of leukemia and other tumors |
| Q89966656 | T-cells with a single tumor antigen-specific T-cell receptor can be generated in vitro from clinically relevant stem cell sources |
| Q36982946 | TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. |
| Q34261346 | The possible role and application of WT1 in human leukemia |
| Q34820049 | The role of WT1 in oncogenesis: tumor suppressor or oncogene? |
| Q39981660 | The transcriptional activity of WT1 gene promoter and enhancer in cell lines with diverse tissue origin |
| Q36919619 | Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients |
| Q36793112 | Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias |
| Q36989720 | Update on vaccine development for renal cell cancer |
| Q37842342 | Vaccines as consolidation therapy for myeloid leukemia. |
| Q33814519 | WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phase |
| Q36198150 | WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides |
| Q82808308 | WT1(235), a ninemer peptide derived from Wilms' tumor gene product, is a candidate peptide for the vaccination of HLA-A*0201-positive patients with hematopoietic malignancies |
| Q37574653 | Wilms tumor 1 peptide vaccination after hematopoietic stem cell transplant in leukemia patients |
| Q34820008 | Wilms tumor gene (WT1) expression as a panleukemic marker |
| Q34498299 | Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer |
| Q73743100 | Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis |
| Q34617770 | Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses |
| Q34261302 | Wilms' tumor gene WT1: its oncogenic function and clinical application |